AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph beginning at page 19, line 7, as follows:

Recombinant Ty VLPs expressing the pb9 epitope from *P. berghei* CS, SIPSAEKI (SEQ ID NO:1), were prepared as described in [Gilbert et al., (1997) Nat. Biotechnol. 15(12): 1280-4] and suspended in PBS.

Please amend the paragraph beginning at page 20, line 6, as follows:

The number of IFN-γ secreting, pb9-specific T cells in fresh splenocyte preparations was determined as described previously [Schneider et al., (1998) Nat. Med. 4(4): 397-402] by coating 96-well nitrocellulose plates with anti-mouse ~~IFN-γantibody~~ IFN-γ antibody (clone R4 from ETCC), washing with PBS and subsequent blocking with complete medium containing 10% FCS. Splenocytes from immunized mice were resuspended at 1-2 x 10^7 cells/ml and placed in duplicates into the coated wells, and serially diluted. The H2-K^d –restricted peptide pb9 (SYIPSAEKI) (SEQ ID NO:1) (Romero) was added to test wells and an irrelevant peptide to control wells. After overnight incubation the wells were washed and a second, biotinylated anti-IFN-γ antibody (Pharmigen clone) added to the wells. The wells were washed again and streptavidin-alkaline phosphatase was added. After further washing, spots were developed by adding an alkaline phosphatase substrate. The reaction was stopped by washing the wells and spots were counted under a stereomicroscope.

Before the Figures, insert the Sequence Listing submitted herewith.